The small-molecule respiratory drugs market is projected to grow from USD 43,919.2 million in 2026 to USD 83,219.8 million by 2036, at a CAGR of 6.6%. Bronchodilators will dominate with a 38.0% market share, while asthma will lead the applications segment with a 25.0% share.